Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67(6):1099–109.

Article  PubMed  Google Scholar 

Creta M, Russo GI, Bhojani N, Drake MJ, Gratzke C, Peyronnet B, et al. Bladder outlet obstruction relief and symptom improvement following medical and surgical therapies for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review. Eur Urol. 2024;86:315–26.

Article  PubMed  Google Scholar 

Fusco F, Palmieri A, Ficarra V, Giannarini G, Novara G, Longo N, et al. α1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69(6):1091–101.

Article  CAS  PubMed  Google Scholar 

Andriole G, Bruchovsky N, Chung LWK, Matsumoto AM, Rittmaster R, Roehrborn C, et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004;172(4 Part 1):1399–403.

Article  CAS  PubMed  Google Scholar 

Giuliano F, Ückert S, Maggi M, Birder L, Kissel J, Viktrup L. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2013;63(3):506–16.

Article  CAS  PubMed  Google Scholar 

Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. In: The Cochrane Collaboration, editor. Cochrane Database of Systematic Reviews. Chichester: Wiley; 2009 [cité 23 août 2024]. p. CD001423.pub2. https://doi.org/10.1002/14651858.CD001423.pub2

Lee CL, Shin H, Lee JY, Kwon O, Seo C, Kim A, et al. Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: a double-blinded, randomized, pilot clinical trial. Int J Urol. 2022;29(6):503–9.

Article  PubMed  PubMed Central  Google Scholar 

Hızlı F, Uygur MC. A prospective study of the efficacy of Serenoa repens, Tamsulosin, and Serenoa repens plus Tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol. 2007;39(3):879–86.

Article  PubMed  Google Scholar 

McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

Article  CAS  PubMed  Google Scholar 

Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61(1):119–26.

Article  PubMed  Google Scholar 

Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.

Article  CAS  PubMed  Google Scholar 

Barkin J. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride. Eur Urol. 2003;44(4):461–6.

Article  CAS  PubMed  Google Scholar 

Joo KJ, Sung WS, Park SH, Yang WJ, Kim TH. Comparison of α-blocker monotherapy and α-blocker plus 5α-reductase inhibitor combination therapy based on prostate volume for treatment of benign prostatic hyperplasia. J Int Med Res. 2012;40(3):899–908.

Article  CAS  PubMed  Google Scholar 

Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335(8):533–40.

Article  CAS  PubMed  Google Scholar 

Hagiwara K, Koie T, Iwamura H, Imai A, Hatakeyama S, Yoneyama T, et al. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. Biomed Res Int. 2016;2016:1–5.

Article  CAS  Google Scholar 

Kaplan SA, McCammon K, Fincher R, Fakhoury A, He W. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency. J Urol. 2009;182(6):2825–30.

Article  PubMed  Google Scholar 

MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83(9):1002–10.

Article  CAS  PubMed  Google Scholar 

Van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, et al. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol. 2013;64(6):1003–12.

Article  PubMed  Google Scholar 

Drake MJ, Chapple C, Sokol R, Oelke M, Traudtner K, Klaver M, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol. 2015;67(2):262–70.

Article  CAS  PubMed  Google Scholar 

Jin Z, Zhang ZC, Liu JH, Lu J, Tang YX, Sun XZ, et al. An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Asian J Androl. 2011;13(4):630–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 2016;13(6):2920–6.

PubMed  Google Scholar 

AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022;40(8):2063–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao Y, Wang Y, Guo L, Yang X, Chen T, Niu H. A randomized, open-label, comparative study of efficacy and safety of tolterodine combined with tamsulosin or doxazosin in patients with benign prostatic hyperplasia. Med Sci Monit. 2016;22:1895–902.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kakizaki H, Lee KS, Yamamoto O, Jong JJ, Katou D, Sumarsono B, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2020;6(4):729–37.

Article  PubMed  Google Scholar 

Yamanishi T, Kaga K, Sakata K, Yokoyama T, Kageyama S, Fuse M, et al. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study). Neurourol Urodyn. 2020;39(2):804–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamanishi T, Asakura H, Seki N, Tokunaga S. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study). LUTS. 2019;11(3):115–21.

Article  CAS  PubMed  Google Scholar 

Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. Effectiveness of solifenacin and trospium for managing of severe symptoms of overactive bladder in patients with benign prostatic hyperplasia. Am J Mens Health. 2016;10(2):157–63.

Article  PubMed  Google Scholar 

Gravas S, Malde S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, et al. From BPH to male LUTS: a 20-year journey of the EAU guidelines. Prostate Cancer Prostatic Dis. 2024;27(1):48–53. https://doi.org/10.1038/s41391-023-00700-3. (Epub 2023 Jul 24).

Article  PubMed  Google Scholar 

Lenfant L, Pinar U, Roupret M, Mozer P, Chartier-Kastler E, Seisen T. Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: an updated systematic review and meta-analysis. J Urol. 2023;209(2):314–24. https://doi.org/10.1097/JU.0000000000003077. (Epub 2022 Nov 17).

Article  PubMed  Google Scholar 

Kang TW, Kim SJ, Kim MH, Jung JH. Beta 3 adrenoreceptor agonist for the management of lower urinary tract symptoms in men with benign prostatic hyperplasia: a systematic review. Int Neurourol J. 2021;25(3):182–91. https://doi.org/10.5213/inj.2142068.034. (Epub 2021 Sep 30).

Article